Am J Perinatol 2017; 34(4): 340-348
DOI: 10.1055/s-0036-1586501
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Universal Prenatal Chromosomal Microarray Analysis: Additive Value and Clinical Dilemmas in Fetuses with a Normal Karyotype

Eran Bornstein
1   Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Lenox-Hill Hospital, New York, New York
,
Sharon Berger
1   Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Lenox-Hill Hospital, New York, New York
,
Sau W. Cheung
2   Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
,
Kristen T. Maliszewski
2   Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
,
Ankita Patel
2   Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
,
Amber N. Pursley
2   Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
,
Erez Lenchner
3   Statistics and Data Management, New York University College of Nursing and College of Dentistry, New York, New York
,
Carlos Bacino
2   Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
,
Arthur L. Beaudet
2   Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas
,
Michael Y. Divon
1   Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Lenox-Hill Hospital, New York, New York
› Institutsangaben
Weitere Informationen

Publikationsverlauf

27. April 2016

23. Juni 2016

Publikationsdatum:
17. August 2016 (online)

Preview

Abstract

Objective To assess the additive value of prenatal chromosomal microarray analysis (CMA) for all indications and the likelihood of detecting pathologic copy number variations (CNVs) based on specific indications.

Methods A retrospective analysis was performed on amniocentesis and chorionic villi sampling results obtained between 2010 and 2014 in a single institution. A total of 3,314 consecutive patients undergoing invasive genetic testing for different indications were offered CMA in addition to standard karyotype. The prevalence of pathologic CNVs was compared between patients with low-risk indications and those with high-risk indications. Likewise, the prevalence of pathologic CNVs among patients with different sonographic abnormalities was calculated and compared with the low-risk group. Chi-square and Fisher exact tests were used for statistical analysis.

Results The prevalence of pathologic CNVs was significantly higher in patients with high-risk indications and specifically those with sonographic abnormalities, compared with the low-risk group (2.8 and 5.9% vs. 0.4%, respectively; all p < 0.05).

Conclusion Prenatal CMA detected clinically relevant CNVs in fetuses with a normal karyotype. Major structural malformations and nuchal translucency (NT) ≥ 3.0 mm are associated with the highest risk for a CMA abnormality. Nevertheless, the prevalence of pathologic CNVs in the low-risk population was high enough (1:250) to consider genetic counseling in this group.